Management of People with HIV and Weight Gain: Module 9

Target Audience 

This activity is intended for infectious disease and HIV specialists engaged in the care of patients with HIV. 

Program Description 

Individuals with HIV frequently experience weight gain related to specific antiretroviral regimens, especially second-generation integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF). Antiretroviral therapy (ART)–related weight gain occurs more frequently in certain populations, namely Black women, and can increase the risk for other comorbidities, such as cardiovascular disease and type 2 diabetes mellitus. Dr. Laura Waters and Dr. Paul Sax review the clinical data to further characterize the association between weight gain and ART and provide helpful approaches for the management of patients with HIV and weight gain in clinical practice.

Educational Objective 

Upon completion of this activity, participants will be better prepared to:

• Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug-drug interactions 
• Employ strategies to manage commonly occurring comorbidities alongside regular HIV management 

Faculty 

Paul E. Sax, MD 
Professor of Medicine
Harvard Medical School
Clinical Director, Division of Infectious Diseases
Brigham and Women’s Hospital
Boston, Massachusetts 

Laura Waters, MD, FRCP 
Consultant Physician, Sexual Heath & HIV
Chair British HIV Association
Mortimer Market Centre
London, United Kingdom 

Disclosure of Conflicts of Interest 

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity: 

Paul E. Sax, MD: 
Consulting Fees/Advisor: Gilead Sciences, Inc., GSK plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., ViiV Healthcare
Research Support: Gilead Sciences, Inc., GSK plc, ViiV Healthcare
Editorial Positions: Clinical Infectious Diseases, UpToDate, NEJM Journal Watch

Laura Waters, MD: 
Consulting Fees/Advisor/Speaker: Cipla Limited, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co, Inc., Mylan Pharmaceuticals, Inc., Theratechnologies Inc., ViiV Healthcare
Researcher: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., ViiV Healthcare 

The PACE planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose. 

Instructions to Receive Credit 

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation. 

Fee Information  

There is no fee for this educational activity. 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Integritas Communications.  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education 

PACE designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Continuing Nursing Education 

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours. 

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 

CME Questions – PACE Contact Information 

For information about the accreditation of this program, please contact PACE https://partnersed.com/

Integritas Contact Information 

For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com. 

Computer System Requirements 

PC
1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above) 

MAC
1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)